Intratumoral CAN1012(Selective TLR7 Agonist) in Subjects With Solid Tumors

Phase 1 Unknown 36 enrolled CanWell Pharma Inc.

NaSingle-groupOpen-labelTreatment

Summary

To evaluate CAN1012(Selective TLR7 agonist) when administered by IT injection to subjects with advanced solid tumors who are not candidates for standard therapy.

Timeline

Start: 2022-01-20
Primary completion: 2024-12-30
Completion: 2024-12-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CAN1012	Unknown	—	Other

Intratumoral CAN1012(Selective TLR7 Agonist) in Subjects With Solid Tumors

Summary

Timeline

Drugs

Indications